Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e48-50. doi: 10.1097/QAI.0000000000000990.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alkynes
  • Anti-HIV Agents / therapeutic use*
  • Atazanavir Sulfate / therapeutic use
  • Benzoxazines / therapeutic use
  • Cyclopropanes
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Emtricitabine / therapeutic use
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Lopinavir / therapeutic use
  • Male
  • Middle Aged
  • RNA, Viral / isolation & purification
  • Raltegravir Potassium / therapeutic use*
  • Ritonavir / therapeutic use
  • Surveys and Questionnaires
  • Tenofovir / therapeutic use
  • Treatment Outcome

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • HIV Protease Inhibitors
  • RNA, Viral
  • Lopinavir
  • Raltegravir Potassium
  • Atazanavir Sulfate
  • Tenofovir
  • Emtricitabine
  • efavirenz
  • Ritonavir

Associated data

  • ClinicalTrials.gov/NCT00752856